Chemotherapy-Induced Nausea and Vomiting Prevention Regimens
Standard Triple-Therapy Regimen
- The American Society of Clinical Oncology recommends a regimen of aprepitant 125 mg orally on Day 1, followed by 80 mg once daily on Days 2-3, combined with granisetron 2 mg orally once daily on Day 1 and dexamethasone 12 mg on Day 1, for highly or moderately emetogenic chemotherapy 1, 2
- The National Comprehensive Cancer Network suggests that granisetron 2 mg orally or 1 mg IV can be used on Day 1, as part of the triple therapy regimen 1, 3
- Dexamethasone dose should be reduced by 50% to 12 mg on Day 1 and 8 mg on subsequent days, due to aprepitant's CYP3A4 interaction, as recommended by the European Society for Medical Oncology 1, 2
Efficacy Data Supporting This Combination
- The aprepitant-based triple therapy regimen demonstrates superior outcomes, with complete response rates of 83-89% for acute emesis and 68-75% for delayed emesis, when combined with a 5-HT3 antagonist and dexamethasone, according to the American College of Clinical Pharmacy 2
- For moderately emetogenic chemotherapy, the overall complete response rate is 51% versus 43% with standard therapy (P = 0.015), as reported by the Multinational Association of Supportive Care in Cancer 2
Critical Drug Interaction Warning
- The American Society of Health-System Pharmacists warns that when combining aprepitant with corticosteroids, the dexamethasone dose must be reduced by approximately 50% because aprepitant inhibits CYP3A4 metabolism 1, 2, 3
Management of Breakthrough Symptoms
- The European Society for Medical Oncology recommends adding dopamine antagonists, such as metoclopramide 20-30 mg or prochlorperazine 10-20 mg, to the existing regimen rather than increasing doses, for managing breakthrough symptoms 1, 3
- Consider adding lorazepam 1-2 mg for anticipatory nausea, as suggested by the National Comprehensive Cancer Network 1